Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We got more work done than we thought we would which is good, it shows, starting to show scale there, really thrilled on the client reaction |
| But feel fairly encouraged, feel like we'll be able to do that early in the year, next year |
| As noted in today's press release, the quarter's financial results came in better than initially expected with revenue growing 8% year-over-year to $16.3 million, which is a record third quarter for the company |
| The improvement was driven by strong organic growth in messaging led by our DAAP enhancement |
| We're encouraged by the quarter-over-quarter improvement on gross margins and it reflects the increase in the business associated with DAAP |
| Moreover, the transaction is accretive to earnings as Medicx is highly profitable company and is expected to contribute meaningful to revenue, revenue growth, EBITDA and earnings per share |
| The Medicx transaction not only positions OptimizeRx to profitably expand our market opportunity, we are also further enhancing our position as a leading player in the digital pharma marketing landscape by meaningfully expanding our channels and reach to unlock value for our customers |
| Given the increase in DAAP and some of these wins that we're seeing from Q3 and Q4 we'll have better visibility as well, so the two will come together nicely |
| With that being said, we're seeing very encouraging momentum heading into the end of the year and going into 2024 |
| We remain confident in our long-term growth outlook and are happy to say we're increasing our guidance for 2023 and are now expecting revenue to come in between $68 million and $70 million with an adjusted EBITDA between $3 million and $4 million |
| So some early wins that are meaningful and sizable and really exciting and I think a good telltale to what 2024 will look like |
| We'll have a lot started going into Q1, which is great, and then we'll probably start more in Q2 on new clients that come out of the RFP season but really happy with the improvement to the range we're in with gross margin and obviously see it drops right down |
| Because of the pick up on the DAAP, which has some architectural work up front, we had a nice positive impact on gross margin |
| So I think it's really an exciting time for the business on the product front, the marketing front and the revenue potential growth is really exciting |
| So we think we're going to have a competitive advantage there |
| We believe we turned a significant corner since the start of the second half of the year and have incredible momentum going into 2024 |
| On a combined basis, revenues are expected to quickly surpass $100 million while generating significant profitability and cash flow |
| I'm sure you could sense our excitement and see our positive momentum from the second half of 2023 and into 2024 |
| Progress here is pacing ahead of what we anticipated, which is best evidenced by the strong GAAP or RWE momentum we've seen during the second half of 2023 |
| Customers who have been exposed to DAAP quickly become our strongest advocates and this success is quickly moving us up the decision maker hierarchy with our larger customers |
| I think that all makes sense and nice to hear the good execution on the marketing side of things as well |
| Given the improving macro environment and the recent customer traction we're seeing with the DAAP enhancement, we believe last month's acquisition of Medicx was perfect timing |
| We will have more details to share once we get through the RFP season, but early indicators are very encouraging as we bring our combined value prop to the market |
| Net revenue retention rate is showing improvement at 93%, up from 89% in Q2 2023 |
| We are well funded to execute against our operational goals |
| I'm pleased to note that Q3 has been an exciting fiscal and operational turning point for OptimizeRx |
| I believe this aligns strongly with our land-and-expand strategy and enables significant upselling and cross selling opportunities, particular when you couple this fact that over 80% of the brands our respective companies support do not overlap |
| We're encouraged by the continued improvement in our KPIs as we move past the external market challenges and return to growth and profitability as a leader in our space |
| So I think we're in a good place |
| I'm happy to report we're ahead of schedule and we have already completed over half our planned cost reductions and have identified the remaining cuts and are in the final stages of executing against our objective |
| Statement |
|---|
| And so when a competitor didn't deliver on what they articulated they would in the first half, it actually caused the brand to lose funds for marketing in the second half of the year, which is a big problem |
| As noted in multiple independent studies, this is one of the top challenges in today's specialty medication driven market |
| Universally, what we're hearing is that other competitors ability to measure effectively, accurately, and timely is really lacking |
| Meanwhile, our gross margin decreased slightly from 62.4% in the quarter ended September 30, 2022 to 60% in quarter ended September 30, 2023 with the difference being largely tied to solution and channel partner mix |
| I mean the only thing that I would say in terms of headwinds, which was the second part of your question was the market headwinds are still there in terms of prevailing issues in the industry, although we've highlighted some of the stuff that we've seen subside |
| And there, as Steve said, there are still headwinds for a lot of firms and if you're a boater it all depends where your boat is when you have the headwinds |
| I think given the economy, the turnover rate in general, if you track LinkedIn you can see people are jumping around a lot less and all those things were headwinds |
| So the scale is an issue |
| They found that to be a huge problem |
| It always has been a challenge |
| Adherence is one of the largest challenges they have |
| The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effects of government regulations, competition and other material risk |
| William Febbo Yes, I'd say, I'd just add to the headwinds, we have seen normalization on the FDA approval rate to back to 2021 |
| The macro headwinds that we identified last year have begun to normalize |
| We would be curious to hear a bit more of what you're seeing with the client base, maybe what's driving that underlying improvement because it seems like others in this space are certainly still calling out some of those headwinds with farmers that have been in place last year four quarters |
| I think the more important thing to probably note here is to put punctuation around the fact that our return on investment measurements have happened and so we've been clear about we would start to see those that were over promising, under delivering in the competitive landscape just start to get sifted out of the market, that definitely happened in the first half of this year |
| We had a net loss of $2.9 million or $0.17 per basic and fully diluted share for the three months ended September 30, 2023 as compared to a net loss of $3.5 million during the same period in 2022 |
| Directionally, this has been no easy feat as OptimizeRx's results have come about through the shifting sands of both the industry changes as well as the early adoption of advancements related to the digital shift which has permanently altered the way pharma, patients and prescribers engage with one another |
| Moreover, our clients that had started initial pilot programs with companies that had newly entered the space over the last 12 to 18 months are now completing the measurement of these programs and as we expected have learned that these solutions are not scalable and are beginning to drive bend back our way |
| That was not anticipated |
Please consider a small donation if you think this website provides you with relevant information